Troubleshooting

What to Do If Your GLP-1 Medication Stops Working

GLP-1 Companion · 8 min read

At some point during GLP-1 therapy, many patients experience a moment where the scale stops moving — or stops moving as quickly as it once did. This often prompts the question: has the medication stopped working? In most cases, the answer is no. Understanding the difference between true non-response and a normal physiological plateau is the first step in knowing how to respond.

True Non-Response vs. Normal Plateau: A Critical Distinction

True non-response is defined clinically as losing less than 5% of body weight after 12–16 weeks at a full therapeutic dose. This is distinct from the much more common experience of reaching a plateau after an initial period of meaningful weight loss. True non-response affects roughly 10–15% of patients. Normal plateau affects virtually everyone at some point during treatment and does not mean the medication has failed.

• True non-response: Less than 5% total weight loss after 12–16 weeks at therapeutic dose. Warrants re-evaluation and potential medication adjustment.
• Normal plateau: Weight loss slows or stalls after initial meaningful loss. Expected physiological adaptation, not medication failure.
• Partial response: More than 5% but less than expected loss. May benefit from dose optimization or lifestyle adjustments.
• Plateau after major loss: Scale stable after achieving 10–20%+ loss. May indicate approaching new set point.

Step 1: Assess Adherence and Injection Technique

Before concluding that the medication is ineffective, a systematic review of treatment adherence is essential. Both missed doses and injection technique errors can substantially reduce the amount of drug actually delivered, producing a pattern that looks like loss of efficacy but is actually inadequate dosing.

• Missed doses: Even one or two missed weekly injections per month meaningfully reduces cumulative drug exposure.
• Injection technique: Not fully pressing the dose button, removing the pen before the full count, or injecting into an area with lipohypertrophy (hardened tissue from repeated injections) reduces absorption.
• Pen priming: Failure to prime the pen before first use can result in air rather than medication being injected.
• Storage errors: Storing the pen in temperatures above 86°F or allowing freezing can degrade the medication.
• Site rotation: Repeatedly injecting in the same small area causes lipohypertrophy, which significantly impairs drug absorption.

Step 2: Review Caloric Intake and Portion Creep

One of the most common causes of plateau after initial good response is gradual caloric creep — the slow and often unconscious increase in food intake that occurs as appetite returns to a new baseline after the initial strong suppression effect. This is not a moral failing; it reflects the body's ongoing efforts to restore energy balance. Regular food journaling or a structured dietary reassessment with a registered dietitian often reveals patterns that are maintaining weight rather than supporting continued loss.

• Liquid calories: Calorie-dense beverages (juice, alcohol, specialty coffees) bypass the satiety signals GLP-1 medications enhance.
• Portion size drift: Portions that started small tend to gradually expand back toward previous norms.
• Processed foods: High-palatability ultraprocessed foods can override GLP-1-mediated satiety signaling.
• Snacking patterns: Returning to snacking between meals adds calories without triggering meaningful satiety.

Step 3: Evaluate Metabolic Adaptation

As body weight drops, total daily energy expenditure (TDEE) decreases. A person who weighs 30 pounds less than they did six months ago burns fewer calories at rest, fewer during exercise, and fewer through non-exercise activity thermogenesis (NEAT) — the unconscious movement that accounts for a substantial portion of daily calorie burn. This metabolic adaptation is a primary driver of plateaus and cannot be "fixed" by the medication alone.

Step 4: Add Resistance Training

Resistance training is the most evidence-supported intervention for breaking a GLP-1 plateau. Skeletal muscle is the largest metabolically active tissue in the body; increasing muscle mass raises resting metabolic rate, partially offsetting metabolic adaptation. Resistance training also improves insulin sensitivity, which complements GLP-1 mechanisms. Patients on GLP-1 medications who do not include resistance training lose a disproportionate amount of lean mass alongside fat, which accelerates the metabolic slowdown.

Step 5: Evaluate Sleep and Stress

Poor sleep and chronic stress are underappreciated contributors to weight loss plateaus even on GLP-1 therapy. Sleep deprivation increases ghrelin (the hunger hormone), decreases leptin (the satiety hormone), elevates cortisol, and impairs glucose metabolism — all of which counteract the mechanisms by which GLP-1 medications work. Chronic stress produces sustained cortisol elevation, which promotes fat storage particularly in the visceral compartment, blunts insulin sensitivity, and increases drive to eat high-calorie foods.

• Sleep: Target 7–9 hours of quality sleep. Screen for sleep apnea if snoring is present.
• Stress: Chronic work, financial, or relationship stress chronically elevates cortisol.
• Mind-body practices: Evidence supports mindfulness-based interventions for stress-related eating.
• Alcohol: Disrupts sleep architecture, adds calories, and temporarily suppresses fat oxidation.

Step 6: Discuss Dose Optimization with Your Provider

If lifestyle factors have been addressed and plateau persists, a dose increase may be appropriate. For patients on semaglutide, escalating from 1mg to 2mg (Ozempic) or from a sub-maximal to the 2.4mg Wegovy dose may renew weight loss. For patients on tirzepatide, moving toward the 10mg or 15mg dose is associated with greater average weight loss in clinical trials. Not all patients reach the maximum approved dose — some cannot tolerate it — but for those who can, it often produces additional loss.

Step 7: Consider Switching to a Dual or Triple Agonist

Patients who have experienced a true non-response or persistent inadequate response on a GLP-1 receptor agonist alone may benefit from switching to tirzepatide (a dual GLP-1/GIP agonist) or, as clinical data matures, to emerging triple agonists like retatrutide (GLP-1/GIP/glucagon). Head-to-head comparison data suggests that tirzepatide produces greater average weight loss than semaglutide, and some patients who responded poorly to GLP-1 alone respond substantially better to dual agonism.

• Semaglutide non-responders may respond to tirzepatide due to the additional GIP mechanism.
• Switching should be done under provider supervision with appropriate dosing.
• Allow 12–16 weeks at a therapeutic dose of the new medication before assessing response.
• Emerging options: retatrutide (triple agonist), cagrilintide combinations, and others are in late-stage trials.

What Does Not Help

Several common strategies are not supported by evidence and may actually worsen plateau outcomes. Extreme caloric restriction is counterproductive — it accelerates muscle loss, drives a further drop in metabolic rate, and is unsustainable. Cardio-only approaches without resistance training do not adequately address the muscle preservation issue. "Medication breaks" or dose cycling have no supporting evidence and expose patients to weight regain. Patience and a systematic, evidence-based approach is consistently more effective than dramatic interventions.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Belsham et al. (2026). Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature.